Organization
Denovo Biopharma
5 clinical trials
1 abstract
Clinical trial
A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant DepressionStatus: Completed, Estimated PCD: 2024-02-06
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1Status: Completed, Estimated PCD: 2024-02-29
Clinical trial
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With SchizophreniaStatus: Completed, Estimated PCD: 2012-08-01
Clinical trial
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM-IV-TR SchizophreniaStatus: Terminated, Estimated PCD: 2012-09-01
Clinical trial
A Long-Term, Phase 2, Multicenter, Randomized, Open-Label Comparative Safety Study of LY2140023 Versus Atypical Antipsychotic Standard of Care in Patients With DSM-IV-TR SchizophreniaStatus: Completed, Estimated PCD: 2010-05-01
Abstract
DGM1 may serve as a novel genetic biomarker of response to enzastaurin in glioblastoma.Org: University of California Irvine, Denovo Biopharma,